OVERVIEW

New and Emerging Agents in ALL and the Evolving Treatment Paradigm is organized by Healthcare Made Practical (HMP) Communications LLC and will be held from Oct 31, 2018 - Oct 31, 2019.

Target Audience:
Designed for hematologists and hematologic oncologists, medical, radiation, and surgical oncologists, and other healthcare professionals (e.g., physicians, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants) who are involved and/or interested in the treatment of patients with hematologic malignancies.

Accreditation:
1.25 CME
1.25 CNE
1.25 CPE

Course Overview:
Acute lymphocytic leukemia (ALL) is the most common type of childhood cancer, predominantly affecting children aged 5 years and under, though the prevalence of ALL rises again in adults over 50 years of age. The heterogeneity of ALL generates unique challenges for optimal therapeutic approaches based on patient age, genetic aberrations, and treatment-related parameters such as the achievement of minimal residual disease (MRD) negativity. Moreover, certain patient subsets are refractory to traditional chemotherapeutic approaches, and the majority of patients who do respond will eventually relapse. New and emerging targeted therapies—including tyrosine kinase inhibitors (TKIs), monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and bispecific T-cell engagers (BiTEs)—offer new hope for improved outcomes in high-risk or relapsed/refractory (R/R) ALL patients. However, the emergence of these novel therapeutic approaches and outcomes measures such as MRD also generate new challenges with regards to implementation in clinical practice and creates knowledge gaps.

This on-demand web archive is initiated to address such ALL-related knowledge and practice gaps among physicians, NPs, and PAs who manage patients with hematologic malignancies.

Course Objectives:
• Describe the clinical-, disease-, and treatment-related factors that influence ALL prognosis and treatment outcomes
• Define the role of minimum residual disease (MRD) in measuring ALL treatment outcomes and utility in clinical practice
• Assess the preclinical and clinical evidence supporting the use of new and emerging targeted therapies in difficult-to-treat/high-risk ALL
• Consider the role of new and emerging targeted agents within the ALL treatment paradigm

Additional details will be posted as soon as they are available.